Skip to content

4891.T

TMS Co.,Ltd.

グロース · 医薬品 · 医薬品 · JP

JPY 107.00
−0.93%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
+8.3%
EPS
+42.4%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
EBITDA
+23.0%
EBIT
+23.3%
Net income
-8.5%
EPS
+1.8%
Free cash flow
-49.2%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026